Cancer Focus Fund Invests $5.1 Million in Starget Pharma to Support Phase 1b Clinical Trial of Novel Peptide Radioligand for Precision Cancer Therapy

Starget Pharma will use investment to move into clinical trials at MD Anderson and other cancer centers.